Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 48Genitourinary 28Other hematologic neoplasm 19Lymphoid 10Gastrointestinal 8Breast 7Myeloid 6Gynecologic 5Tumor-Agnostic 4Sarcoma 4CNS 4Thoracic 2Head & Neck 2Plasma cell 1Other solid neoplasm 1NET 1Endocrine 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Interleukin-2 × Endocrine × Clear all
NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
51 enrolled
EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡